{"title":"Clinical application of continuous infusion of recombinant interleukin-2.","authors":"W H West","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>While preclinical studies suggest a steep dose-response relationship for the anti-cancer effect of recombinant interleukin-2 (rIL-2), translation of dose-intense rIL-2 to humans can be complicated by known toxicities, including hypotension, capillary leak phenomena and fluid retention. In an attempt to develop a manageable approach to dose-intense rIL-2, we have employed a continuous infusion schedule, 18 X 10(6) IU rIL-2/m2/day for five days. This treatment results in marked biological effect, and continuous infusion of rIL-2 alone or in conjunction with lymphokine-activated killer cells can result in complete remission of metastatic renal carcinoma. Treatment with continuous infusion tumour necrosis factor at 60 micrograms/m2/day for three days prior to rIL-2 may be of possible benefit in isolated cases of colon and lung carcinoma, but has not appeared to produce results superior to rIL-2 alone. Addition of tumour-infiltrating lymphocytes has been of benefit in selected cases of melanoma. The most promising combination of biological agents may be rIL-2 in conjunction with alpha-interferon. Ongoing studies involving subcutaneous alpha-interferon during continuous infusion rIL-2 suggest clinical synergy with acceptable toxicity.</p>","PeriodicalId":11941,"journal":{"name":"European journal of cancer & clinical oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of cancer & clinical oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
While preclinical studies suggest a steep dose-response relationship for the anti-cancer effect of recombinant interleukin-2 (rIL-2), translation of dose-intense rIL-2 to humans can be complicated by known toxicities, including hypotension, capillary leak phenomena and fluid retention. In an attempt to develop a manageable approach to dose-intense rIL-2, we have employed a continuous infusion schedule, 18 X 10(6) IU rIL-2/m2/day for five days. This treatment results in marked biological effect, and continuous infusion of rIL-2 alone or in conjunction with lymphokine-activated killer cells can result in complete remission of metastatic renal carcinoma. Treatment with continuous infusion tumour necrosis factor at 60 micrograms/m2/day for three days prior to rIL-2 may be of possible benefit in isolated cases of colon and lung carcinoma, but has not appeared to produce results superior to rIL-2 alone. Addition of tumour-infiltrating lymphocytes has been of benefit in selected cases of melanoma. The most promising combination of biological agents may be rIL-2 in conjunction with alpha-interferon. Ongoing studies involving subcutaneous alpha-interferon during continuous infusion rIL-2 suggest clinical synergy with acceptable toxicity.
虽然临床前研究表明重组白细胞介素-2 (il -2)的抗癌作用具有明显的剂量-反应关系,但将高剂量il -2翻译给人可能会出现已知的毒性,包括低血压、毛细血管渗漏现象和液体潴留。为了开发一种可管理的方法来治疗剂量高的rIL-2,我们采用了连续输注方案,18 X 10(6) IU rIL-2/m2/天,持续5天。这种治疗产生显著的生物学效应,持续输注rIL-2单独或联合淋巴因子激活的杀伤细胞可导致转移性肾癌完全缓解。在单独的结肠癌和肺癌病例中,持续输注肿瘤坏死因子(60微克/平方米/天,连续3天)治疗rIL-2可能会有好处,但似乎并没有产生比单独使用rIL-2更好的结果。肿瘤浸润淋巴细胞的加入对某些黑色素瘤病例有益。最有希望的生物制剂组合可能是il -2与α -干扰素联合使用。正在进行的关于持续输注il -2时皮下α -干扰素的研究表明,临床协同作用具有可接受的毒性。